McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
SAN DIEGO and TORONTO, Jan. 05, 2017 -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the upcoming Biotech ShowcaseTM 2017 Conference on Tuesday, January 10th at 9:00 a.m. PST in San Francisco, CA.
Conference Presentation Details:
| Date: | Tuesday, January 10, 2017 | ||||||||||||
| Time: | 9:00 a.m. PST | ||||||||||||
| Location: | Track 2 - Ballroom Level | ||||||||||||
| Hilton San Francisco Union Square, 333 O’Farrell Street, San Francisco, CA 94102 | |||||||||||||
| Webcast: | https://event.webcasts.com/viewer/event.jsp?ei=1130686 | ||||||||||||
The audio webcast will be archived shortly after the live event and will be available through the Aptose website at www.aptose.com.
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with companion diagnostics to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.
For further information, please contact: Aptose Biosciences Greg Chow, CFO 647-479-9828 [email protected] SMP Communications Susan Pietropaolo O: 845-638-6290 M: 201-923-2049 [email protected]
